{"id":71745,"date":"2026-08-05T15:25:48","date_gmt":"2026-08-05T07:25:48","guid":{"rendered":"https:\/\/flcube.com\/?p=71745"},"modified":"2026-08-05T15:25:49","modified_gmt":"2026-08-05T07:25:49","slug":"leads-biolabs-trispecific-t-cell-engager-lbl-051-enters-phase-ia-trial-for-refractory-autoimmune-diseases-through-oblenio-bio-partnership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71745","title":{"rendered":"Leads Biolabs&#8217; Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Nanjing Leads Biolabs Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/9887:HKG\">HKG: 9887<\/a>) announced that <strong>Oblenio Bio<\/strong>, a NewCo jointly established with <strong>Aditum Bio<\/strong>, has initiated a <strong>Phase Ia first-in-human clinical trial<\/strong> of <strong>LBL-051<\/strong> in Europe for the treatment of various <strong>refractory autoimmune diseases<\/strong>. LBL-051 is a <strong>trispecific T-cell engager (TCE)<\/strong> targeting <strong>BCMA, CD19, and CD3<\/strong>, designed to safely achieve deep depletion of both B cells and plasma cells, potentially inducing <strong>long-term drug-free remission<\/strong> through durable immune system reset.<\/p>\n\n\n\n<h2 id=\"h-development-milestone\" class=\"wp-block-heading\">Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase Ia (first-in-human)<\/td><\/tr><tr><td><strong>Geography<\/strong><\/td><td>Europe<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Refractory autoimmune diseases<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>LBL-051 (trispecific T-cell engager)<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>BCMA, CD19, and CD3<\/td><\/tr><tr><td><strong>Development Entity<\/strong><\/td><td>Oblenio Bio (NewCo with Aditum Bio)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-mechanism-amp-innovation-profile\" class=\"wp-block-heading\">Drug Mechanism &amp; Innovation Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Architecture<\/strong>: Trispecific T-cell engager (TCE) with three distinct binding domains<\/li>\n\n\n\n<li><strong>Target Strategy<\/strong>:<\/li>\n\n\n\n<li><strong>CD19<\/strong>: Expressed on B cells throughout development<\/li>\n\n\n\n<li><strong>BCMA<\/strong>: Highly expressed on plasma cells<\/li>\n\n\n\n<li><strong>CD3<\/strong>: T-cell receptor component enabling T-cell engagement<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Simultaneous targeting enables comprehensive depletion of both B-cell and plasma cell compartments<\/li>\n\n\n\n<li><strong>Key Innovation<\/strong>: Potential to achieve <strong>durable immune system reset<\/strong> leading to <strong>drug-free remission<\/strong><\/li>\n\n\n\n<li><strong>Safety Advantage<\/strong>: Preclinical data showed <strong>extremely low levels of cytokine release<\/strong>, addressing a major safety concern with T-cell engagers<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-evidence\" class=\"wp-block-heading\">Preclinical Evidence<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy<\/strong>: Complete clearance of B cells and plasma cells demonstrated in preclinical models<\/li>\n\n\n\n<li><strong>Safety<\/strong>: Extremely low cytokine release levels compared to conventional bispecific approaches<\/li>\n\n\n\n<li><strong>Mechanistic Validation<\/strong>: Dual-targeting strategy (CD19 + BCMA) confirmed superior target coverage versus single-target approaches<\/li>\n\n\n\n<li><strong>Therapeutic Window<\/strong>: Favorable safety profile supports clinical advancement in autoimmune indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-framework\" class=\"wp-block-heading\">Strategic Partnership Framework<\/h2>\n\n\n\n<h3 id=\"h-licensing-agreement-november-2024\" class=\"wp-block-heading\">Licensing Agreement (November 2024)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Parties<\/strong>: Leads Biolabs and Oblenio Bio (U.S.-based company founded with Aditum Bio)<\/li>\n\n\n\n<li><strong>Scope<\/strong>: Exclusive global license for LBL-051<\/li>\n\n\n\n<li><strong>Rights Granted<\/strong>: Development, manufacturing, and commercialization worldwide<\/li>\n\n\n\n<li><strong>Strategic Rationale<\/strong>: Leverages Oblenio Bio&#8217;s expertise in autoimmune disease development and global regulatory pathways<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-partnership-benefits\" class=\"wp-block-heading\">Partnership Benefits<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Risk Sharing<\/strong>: Development costs and regulatory risks distributed across partners<\/li>\n\n\n\n<li><strong>Global Reach<\/strong>: Immediate access to international markets through U.S.-based entity<\/li>\n\n\n\n<li><strong>Expertise Alignment<\/strong>: Combines Leads Biolabs&#8217; innovative platform with Oblenio Bio&#8217;s autoimmune disease focus<\/li>\n\n\n\n<li><strong>Capital Efficiency<\/strong>: Enables Leads Biolabs to advance multiple pipeline assets simultaneously<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autoimmune Disease Burden<\/strong>: Refractory autoimmune conditions represent significant unmet medical need with limited treatment options<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Immunosuppressive therapies with chronic administration requirements and significant side effects<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: First-in-class trispecific approach offers potential for curative-like outcomes<\/li>\n\n\n\n<li><strong>Market Potential<\/strong>: Drug-free remission represents paradigm shift with premium pricing potential<\/li>\n\n\n\n<li><strong>Therapeutic Breadth<\/strong>: Platform applicable across multiple autoimmune indications (lupus, rheumatoid arthritis, etc.)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-development-strategy\" class=\"wp-block-heading\">Forward Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase Ia Focus<\/strong>: Safety, tolerability, and preliminary efficacy in refractory autoimmune patients<\/li>\n\n\n\n<li><strong>Dose Escalation<\/strong>: Careful assessment of cytokine release syndrome risk despite favorable preclinical profile<\/li>\n\n\n\n<li><strong>Biomarker Strategy<\/strong>: Comprehensive immune monitoring to validate mechanism of action<\/li>\n\n\n\n<li><strong>Next Milestones<\/strong>: Phase Ib\/II expansion studies expected upon successful Phase Ia completion<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Potential for breakthrough therapy designation given high unmet need<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial progress, partnership benefits, and commercial potential. Actual outcomes may differ due to risks including clinical trial results, regulatory decisions, competitive dynamics, and partnership execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080401900_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026080401900_c.\"><\/object><a id=\"wp-block-file--media-affd558b-0f40-403c-a25a-f66c06aa0037\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080401900_c.pdf\">2026080401900_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080401900_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-affd558b-0f40-403c-a25a-f66c06aa0037\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that Oblenio Bio, a NewCo jointly established&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[1978,65,62,4242,1974,1979,2790],"class_list":["post-71745","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-aditum-bio","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-hkg-9887","tag-leads-biolabs","tag-oblenio-bio","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Leads Biolabs&#039; Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that Oblenio Bio, a NewCo jointly established with Aditum Bio, has initiated a Phase Ia first-in-human clinical trial of LBL-051 in Europe for the treatment of various refractory autoimmune diseases. LBL-051 is a trispecific T-cell engager (TCE) targeting BCMA, CD19, and CD3, designed to safely achieve deep depletion of both B cells and plasma cells, potentially inducing long-term drug-free remission through durable immune system reset.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71745\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leads Biolabs&#039; Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership\" \/>\n<meta property=\"og:description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that Oblenio Bio, a NewCo jointly established with Aditum Bio, has initiated a Phase Ia first-in-human clinical trial of LBL-051 in Europe for the treatment of various refractory autoimmune diseases. LBL-051 is a trispecific T-cell engager (TCE) targeting BCMA, CD19, and CD3, designed to safely achieve deep depletion of both B cells and plasma cells, potentially inducing long-term drug-free remission through durable immune system reset.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71745\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T07:25:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T07:25:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71745#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71745\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Leads Biolabs&#8217; Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership\",\"datePublished\":\"2026-08-05T07:25:48+00:00\",\"dateModified\":\"2026-08-05T07:25:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71745\"},\"wordCount\":522,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Aditum Bio\",\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"HKG: 9887\",\"Leads Biolabs\",\"Oblenio Bio\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71745#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71745\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71745\",\"name\":\"Leads Biolabs' Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-05T07:25:48+00:00\",\"dateModified\":\"2026-08-05T07:25:49+00:00\",\"description\":\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that Oblenio Bio, a NewCo jointly established with Aditum Bio, has initiated a Phase Ia first-in-human clinical trial of LBL-051 in Europe for the treatment of various refractory autoimmune diseases. LBL-051 is a trispecific T-cell engager (TCE) targeting BCMA, CD19, and CD3, designed to safely achieve deep depletion of both B cells and plasma cells, potentially inducing long-term drug-free remission through durable immune system reset.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71745#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71745\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71745#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leads Biolabs&#8217; Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Leads Biolabs' Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that Oblenio Bio, a NewCo jointly established with Aditum Bio, has initiated a Phase Ia first-in-human clinical trial of LBL-051 in Europe for the treatment of various refractory autoimmune diseases. LBL-051 is a trispecific T-cell engager (TCE) targeting BCMA, CD19, and CD3, designed to safely achieve deep depletion of both B cells and plasma cells, potentially inducing long-term drug-free remission through durable immune system reset.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71745","og_locale":"en_US","og_type":"article","og_title":"Leads Biolabs' Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership","og_description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that Oblenio Bio, a NewCo jointly established with Aditum Bio, has initiated a Phase Ia first-in-human clinical trial of LBL-051 in Europe for the treatment of various refractory autoimmune diseases. LBL-051 is a trispecific T-cell engager (TCE) targeting BCMA, CD19, and CD3, designed to safely achieve deep depletion of both B cells and plasma cells, potentially inducing long-term drug-free remission through durable immune system reset.","og_url":"https:\/\/flcube.com\/?p=71745","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-05T07:25:48+00:00","article_modified_time":"2026-08-05T07:25:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71745#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71745"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Leads Biolabs&#8217; Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership","datePublished":"2026-08-05T07:25:48+00:00","dateModified":"2026-08-05T07:25:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71745"},"wordCount":522,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Aditum Bio","Auto-immune","Clinical trial approval \/ initiation","HKG: 9887","Leads Biolabs","Oblenio Bio","T cell engager"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71745#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71745","url":"https:\/\/flcube.com\/?p=71745","name":"Leads Biolabs' Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-05T07:25:48+00:00","dateModified":"2026-08-05T07:25:49+00:00","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that Oblenio Bio, a NewCo jointly established with Aditum Bio, has initiated a Phase Ia first-in-human clinical trial of LBL-051 in Europe for the treatment of various refractory autoimmune diseases. LBL-051 is a trispecific T-cell engager (TCE) targeting BCMA, CD19, and CD3, designed to safely achieve deep depletion of both B cells and plasma cells, potentially inducing long-term drug-free remission through durable immune system reset.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71745#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71745"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71745#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Leads Biolabs&#8217; Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71745"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71745\/revisions"}],"predecessor-version":[{"id":71749,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71745\/revisions\/71749"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}